Cargando…
Relapses Children’s Acute Lymphoblastic Leukemia, Single Center Experience
The prognosis in children and adolescents with relapsed ALL, despite intensive therapy, including hematopoietic stem cell transplantation, is still challenging. This study aims to analyze the incidence of relapsed ALL and survival rates in correlation to the risk factors. Materials and methods: 125...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9776902/ https://www.ncbi.nlm.nih.gov/pubmed/36553318 http://dx.doi.org/10.3390/children9121874 |
_version_ | 1784855972877959168 |
---|---|
author | Stolpa, Weronika Zapała, Magdalena Zwiernik, Bartosz Mizia-Malarz, Agnieszka |
author_facet | Stolpa, Weronika Zapała, Magdalena Zwiernik, Bartosz Mizia-Malarz, Agnieszka |
author_sort | Stolpa, Weronika |
collection | PubMed |
description | The prognosis in children and adolescents with relapsed ALL, despite intensive therapy, including hematopoietic stem cell transplantation, is still challenging. This study aims to analyze the incidence of relapsed ALL and survival rates in correlation to the risk factors. Materials and methods: 125 pediatric patients with ALL diagnosed in our department between 2000-2018; age 1–18 years old (median 6.4); female 53.6% vs. male 46.4%. Results: 19 pts (15.2%) were diagnosed with a relapse. Three pts (15.8%) had been diagnosed with very early relapses (2/3 T-ALL), 12 pts (63.1%) as an early relapse, and 4 pts (21.1%) as a late relapse. Bone marrow was the most frequent relapses localization. The five-year survival has been achieved by six patients (31.6%). A significant difference was found in regard to the five-year overall survival and relapse type (p < 0.05). The group with very early relapses (3/3; 100%) has not reached the five-year survival. Conclusions: 1. The main prognostic factor in children’s ALL relapses is still the time of the onset of the relapse. 2. The T lineage acute lymphoblastic leukemia is a worse prognostic factor. 3. The analysis of the above relapse risk factors alongside cytogenethic markers and flow cytometry or polymerase chain reaction minimal residual disease is very important for first-line chemotherapy improvement and a more personalized choice of therapy for ALL patients. |
format | Online Article Text |
id | pubmed-9776902 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-97769022022-12-23 Relapses Children’s Acute Lymphoblastic Leukemia, Single Center Experience Stolpa, Weronika Zapała, Magdalena Zwiernik, Bartosz Mizia-Malarz, Agnieszka Children (Basel) Article The prognosis in children and adolescents with relapsed ALL, despite intensive therapy, including hematopoietic stem cell transplantation, is still challenging. This study aims to analyze the incidence of relapsed ALL and survival rates in correlation to the risk factors. Materials and methods: 125 pediatric patients with ALL diagnosed in our department between 2000-2018; age 1–18 years old (median 6.4); female 53.6% vs. male 46.4%. Results: 19 pts (15.2%) were diagnosed with a relapse. Three pts (15.8%) had been diagnosed with very early relapses (2/3 T-ALL), 12 pts (63.1%) as an early relapse, and 4 pts (21.1%) as a late relapse. Bone marrow was the most frequent relapses localization. The five-year survival has been achieved by six patients (31.6%). A significant difference was found in regard to the five-year overall survival and relapse type (p < 0.05). The group with very early relapses (3/3; 100%) has not reached the five-year survival. Conclusions: 1. The main prognostic factor in children’s ALL relapses is still the time of the onset of the relapse. 2. The T lineage acute lymphoblastic leukemia is a worse prognostic factor. 3. The analysis of the above relapse risk factors alongside cytogenethic markers and flow cytometry or polymerase chain reaction minimal residual disease is very important for first-line chemotherapy improvement and a more personalized choice of therapy for ALL patients. MDPI 2022-11-30 /pmc/articles/PMC9776902/ /pubmed/36553318 http://dx.doi.org/10.3390/children9121874 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Stolpa, Weronika Zapała, Magdalena Zwiernik, Bartosz Mizia-Malarz, Agnieszka Relapses Children’s Acute Lymphoblastic Leukemia, Single Center Experience |
title | Relapses Children’s Acute Lymphoblastic Leukemia, Single Center Experience |
title_full | Relapses Children’s Acute Lymphoblastic Leukemia, Single Center Experience |
title_fullStr | Relapses Children’s Acute Lymphoblastic Leukemia, Single Center Experience |
title_full_unstemmed | Relapses Children’s Acute Lymphoblastic Leukemia, Single Center Experience |
title_short | Relapses Children’s Acute Lymphoblastic Leukemia, Single Center Experience |
title_sort | relapses children’s acute lymphoblastic leukemia, single center experience |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9776902/ https://www.ncbi.nlm.nih.gov/pubmed/36553318 http://dx.doi.org/10.3390/children9121874 |
work_keys_str_mv | AT stolpaweronika relapseschildrensacutelymphoblasticleukemiasinglecenterexperience AT zapałamagdalena relapseschildrensacutelymphoblasticleukemiasinglecenterexperience AT zwiernikbartosz relapseschildrensacutelymphoblasticleukemiasinglecenterexperience AT miziamalarzagnieszka relapseschildrensacutelymphoblasticleukemiasinglecenterexperience |